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Abstract
Background—In the United States, hepatitis C virus (HCV) infection is most prevalent among 
adults born from 1945 through 1965, and approximately 50% to 75% of infected adults are 
unaware of their infection.
Objective—To estimate the cost-effectiveness of birth-cohort screening.
Design—Cost-effectiveness simulation.
Data Sources—National Health and Nutrition Examination Survey, U.S. Census, Medicare 
reimbursement schedule, and published sources.
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Intervention—One-time antibody test of 1945–1965 birth cohort.
Outcome Measures—Numbers of cases that were identified and treated and that achieved a 
sustained viral response; liver disease and death from HCV; medical and productivity costs; 
quality-adjusted life-years (QALYs); incremental cost-effectiveness ratio (ICER).
Results of Base-Case Analysis—Compared with the status quo, birth-cohort screening 
identified 808 580 additional cases of chronic HCV infection at a screening cost of $2874 per case 
identified. Assuming that birth-cohort screening was followed by pegylated interferon and 
ribavirin (PEG-IFN + R) for treated patients, screening increased QALYs by 348 800 and costs by 
$5.5 billion, for an ICER of $15 700 per QALY gained. Assuming that birth-cohort screening was 
followed by direct-acting antiviral plus PEG-IFN + R treatment for treated patients, screening 
increased QALYs by 532 200 and costs by $19.0 billion, for an ICER of $35 700 per QALY saved.
Results of Sensitivity Analysis—The ICER of birth-cohort screening was most sensitive to 
sustained viral response of antiviral therapy, the cost of therapy, the discount rate, and the QALY 
losses assigned to disease states.
Limitation—Empirical data on screening and direct-acting antiviral treatment in real-world 
clinical settings are scarce.
Conclusion—Birth-cohort screening for HCV in primary care settings was cost-effective.
Primary Funding Source—Division of Viral Hepatitis, Centers for Disease Control and 
Prevention.
Approximately 4.1 million Americans are antibody-positive for hepatitis C virus (HCV), and 
approximately 75% of them are chronically infected; most of the latter were infected 20 to 
40 years ago, before the discovery of HCV (1). In 2005, hepatitis C resulted in 7000 to 13 
000 deaths (2–7). Because HCV progresses slowly, the risk for serious complications is 
increasing among infected Americans as time passes (8). Without changes in current case 
identification and treatment, deaths from HCV are forecasted to increase to 35 000 annually 
by 2030 (5).
In clinical trials, antiviral therapy with pegylated interferon and ribavirin (PEG-IFN + R) has 
resulted in a sustained viral response (SVR) (that is, cure) of HCV infection in 46% of 
patients infected with genotype 1 (which infects 70% and 90% of chronically infected white 
and African American persons in the United States, respectively) and as many as 81% of 
those infected with genotypes 2 or 3 (9, 10). Treatment with PEG-IFN + R is cost-effective 
at these rates of efficacy (11).
The Centers for Disease Control and Prevention currently recommends antibody screening 
of persons with past behaviors, exposures, or health indicators associated with HCV 
infection, such as a history of injection-drug use, hemodialysis, or elevated alanine 
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aminotransferase levels (12). Despite these recommendations, only 25% to 50% of patients 
with chronic hepatitis C are aware of their infection (12–16). Low case identification may 
result from difficulty in implementing risk-based screening given the limited time of primary 
care visits and the awkwardness of discussing behavioral risks.
Expanding screening recommendations to cover the birth cohort born from 1945 through 
1965 (among whom HCV prevalence is highest) offers a potential complement to current 
risk-based screening recommendations. However, although birth-cohort screening would 
increase health care costs by increasing the number of persons screened, the extent to which 
it would translate into health benefits is unknown. Currently, many diagnosed patients forgo 
treatment because of contraindications, inability to pay, lack of specialist access, or personal 
choice (17–20). Further, the effectiveness of antiviral therapy in community settings is lower 
than in clinical trials (17, 21–23).
In this article, we used a previously validated simulation model to estimate the cost-
effectiveness of birth-cohort screening for HCV in the United States (5). Our results can be 




We programmed (Microsoft Visual Studio 2008, Redmond, Washington) a Markov chain 
Monte Carlo simulation model of the prevalence of hepatitis C antibody stratified by age, 
sex, race/ethnicity, and history of injection-drug use and of the natural history of chronic 
hepatitis C. A more thorough description of the disease components is provided elsewhere 
(5). Briefly, we modeled chronic HCV infection based on Meta-Analysis of Histologic Data 
in Viral Hepatitis (METAVIR) scale units (24). We stratified annual disease progression by 
age at infection, sex, and alcohol consumption history and determined disease progression at 
model initiation by using historical HCV incidence data and published observations of 
annual progression in METAVIR units (Supplement 1, available at www.annals.org) (2, 25). 
Patients who progressed to a METAVIR score of 4 were classified as having cirrhosis and 
experienced subsequent annual probability of 0.039 for progressing to decompensated 
cirrhosis (DCC) and a probability of 0.025 for developing hepatocellular carcinoma (HCC) 
(3, 26). Patients with DCC or HCC experienced an annual probability of transplantation or 
death (27–29). Data reported in Supplement 1 were obtained from multiple sources (30–48).
Model Cohorts
We modeled the U.S. population that was born from 1945 through 1965 and had at least 1 
primary care visit in 2006. Using data from the National Health and Nutrition Examination 
Survey (NHANES, for 2001 through 2006), we divided this population into 40 mutually 
exclusive groups stratified by age, race/ethnicity, history of injection-drug use, and 
prescription drug coverage (49). We further stratified these cohorts into those with and those 
without antibody to HCV and divided those with antibodies into those with chronic (75%) 
and those with cleared (25%) infections (8, 49). We estimated that 28% of chronically 
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infected patients were already aware of their infection and would not benefit from additional 
screening (13–16).
Background Mortality
We used census life-tables to calculate the annual probability of mortality from nonhepatic 
causes (50). We multiplied this background mortality probability by 1.42 for people aged 40 
years or older who reported ever injecting drugs. The relative risk for death was equal to a 
weighted average of the relative risk for death of inactive users (assumed to be 1.00) and that 
of active users; it was weighted by the proportion of people who admitted ever injecting 
drugs in the NHANES who did and did not report use within the past 12 months (49, 51).
Screening and Treatment Scenarios
We simulated 4 scenarios: 1) no screening or treatment; 2) risk-based screening, in which 
18.5% (1% per year over the next 20 years) of persons unaware of their chronic infection 
were screened and offered PEG-IFN + R treatment if identified; 3) birth-cohort screening in 
which all people born from 1945 through 1965 and unaware of their HCV antibody status 
were offered 1-time HCV antibody screening during their 2006 primary care visit, then were 
offered PEG-IFN + R treatment if identified; and 4) an identical birth-cohort screening 
scenario in which patients with genotype 1 disease who initiated treatment received direct-
acting antiviral (DAA) treatment in addition to standard therapy and patients with genotypes 
2 and 3 received PEG-IFN + R. Screening occurred once to identify prevalent cases. We did 
not consider repeated screenings because birth-cohort screening is not a useful strategy to 
prevent HCV incidence.
Screening, Contraindication, and Antiviral Initiation
We assumed that 91% of those offered screening would accept it, 90% of those who tested 
positive would receive those results, and all patients with prescription drug insurance 
coverage (87.6%) and no patients without prescription coverage would be considered for 
treatment (30, 49). We estimated that 23.1% of patients considered for treatment were 
contraindicated for modifiable reasons (such as substance abuse or major depression), 11.5% 
were contraindicated for nonmodifiable reasons (such as uncontrolled diabetes or 
autoimmune disorders), and 8.5% declined treatment (20, 31). After adjustment for these 
barriers, 40.8% of positive patients offered testing accepted, were identified, and initiated 
treatment.
Effectiveness of Antiviral Therapy
We set SVR rates for standard therapy to the average of that reported in 4 studies of antiviral 
therapy administered in primary care settings, yielding an SVR rate of 0.33 for genotypes 
1/4 and 0.69 for genotypes 2/3 (17, 22, 43, 52). We set the SVR rate for DAA plus standard 
therapy to 0.54, a value equal to the ratio of the average SVR rate of standard therapy (0.33) 
divided by the SVR of standard therapy observed in clinical trials (0.46) multiplied by the 
SVR rate observed for 12-week DAA plus PEG-IFN + R treatment in clinical trial data 
(0.75) (32).
Rein et al. Page 4














Diagnosed patients with insurance who did not undergo antiviral therapy or achieve an SVR 
received clinical management described in The Cleveland Clinic Monograph on hepatitis C 
management (39) or the American Association for the Study of Liver Diseases guidelines 
(40). Patients who achieved an SVR also received care in subsequent years. Clinical 
management other than antiviral therapy increased costs but did not result in any modeled 
benefit.
Medical Costs
We estimated screening costs from data provided by a federally qualified health center that 
conducted routine hepatitis B screening of at-risk patients, replacing the reimbursement 
costs for hepatitis B antigen testing with the costs of a hepatitis C antibody testing (38). We 
estimated the costs of standard antiviral therapy as the sum of the average monthly cost of 
PEG-IFN + R observed in the Kaiser Permanente Health System of Georgia in 2009 
multiplied by the estimated months of therapeutic adherence observed in the control group 
of a published therapy-discontinuation study (43, 53). To these costs, we added the estimated 
monthly outpatient and laboratory expenses of treatment as outlined in The Cleveland Clinic 
Monograph on hepatitis C management (39). We estimated the costs of adding DAA to 
standard treatment based on costs and response-based treatment algorithms obtained through 
personal communication (technical report available at www.norc.org/PDFs/Cost-
effectiveness%20of%20BC%20Screening%20Technical%20Report_v7.pdf). We estimated 
the costs of clinical services used to treat patients in each disease stage by converting the 
procedures associated with each disease stage outlined in medical guidelines into their 
corresponding procedure codes. We assigned reimbursement costs to codes based on the 
Medicare fee schedule (39–42).
Productivity Losses
We estimated hours of productivity losses associated with the antiviral therapy by 
multiplying the number of hours per week lost during therapy estimated by 1 source by the 
discontinuation of therapy distribution (in weeks) observed in a second study (54, 55). We 
multiplied weeks of productivity losses by the median weekly wages obtained from the U.S. 
Bureau of Labor Statistics, adjusted by age and sex (56). We also estimated productivity 
losses from end-stage liver disease.
Utility Losses
Persons without hepatitis C experienced a background QALY that decreased as patients aged 
to account for the prevalence of other health conditions (57). For people with HCV, we 
collected utility losses from 5 empirical studies for 7 hepatitis C disease states: SVR, 
METAVIR 0 to 1, METAVIR 2 to 3, compensated cirrhosis, DCC, HCC, and post–liver 
transplantation cirrhosis (58–62). We standardized results for each study by dividing the 
observed QALY value for each HCV state by the QALY value for the no-HCV state. We 
multiplied the mean of the standardized values for each HCV state by the background 
QALY of the patient with disease. For patients receiving antiviral therapy, we again 
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multiplied the patient’s QALY value by 0.88 for patients with genotype 1 and by 0.97 for 
patients with genotype 2 (26).
Simulation, Outcomes, and Sensitivity Analysis
We estimated medical outcomes, costs, and QALYs associated with each scenario, 
accounting for uncertainty in each of the model’s key parameters. We simulated each 
scenario 1000 times, holding prevalence constant and using 1 of 1000 sets of parameters, 
wherein each parameter was selected randomly from its distribution. We report the mean of 
the simulated values for the overall population outcomes and the mean and the empirical 
95% credible interval for per-person costs and QALYs. We used these values to calculate the 
incremental cost-effectiveness ratios (ICERs) and their credible intervals of the birth-cohort 
screening scenario compared with the baseline risk-based scenario. The ICER was 
calculated as the incremental difference in medical cost between 2 scenarios divided by the 
incremental difference in QALYs.
We tested the sensitivity of the ICER of birth-cohort screening with standard treatment 
compared with risk-based (status quo) screening to univariate differences in QALY losses; 
the discount rate; the probability of an SVR for genotypes 1, 2, and 3; the proportion of virus 
that is genotype 1; the cost of screening; and the costs of standard treatment. We tested the 
sensitivity of the ICER of birth-cohort screening with DAA plus standard treatment 
compared with standard treatment alone to univariate differences in the costs and 
effectiveness of treatment.
We calculated cost-effectiveness acceptability curves for willingness-to-pay (WTP) values 
per QALY gained ranging from $0 to $100 000 by calculating the probability that each 
scenario had the greatest net benefit (and thus was the most cost-effective) at each WTP 
value.
Role of the Funding Source
This research was funded by the Centers for Disease Control and Prevention’s Division of 
Viral Hepatitis, which employed 4 authors (Drs. Smith, Patel, Ward, and Weinbaum) who 
participated in conceptualization, review, and revisions.
Results
We estimated that 66.9 million Americans born from 1945 through 1965 visited a primary 
care provider at least once in 2006. Of these, 2.4 million were antibody-positive for HCV, 
1.9 million were chronically infected, and 1.2 million were chronically infected and unaware 
of their status (Supplement 2, available at www.annals.org). With no screening, we estimated 
that 618 000 birth-cohort members would develop DCC or HCC and die of hepatitis. Under 
risk-based screening, 14.8 million persons received antibody screening, 135 000 were 
treated, and 53 000 achieved an SVR. Under risk-based screening, 592 000 birth-cohort 
members developed DCC or HCC and died of hepatitis C.
Under birth-cohort screening with standard treatment, 60.4 million persons received 
antibody testing, 1 070 840 new cases were identified, 552 000 patients were treated, 229 
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000 patients achieved an SVR, and the number of deaths from HCV was reduced to 509 000 
(a decrease of 82 000 deaths compared with risk-based screening). Birth-cohort screening 
increased QALYs by 348 800, medical costs by $5.5 billion, and productivity losses by $6.9 
billion.
Birth-cohort screening with DAA plus standard treatment increased screening, cases 
identified, and persons treated by the same amount as did birth-cohort screening with 
standard treatment, but (compared with risk-based screening) increased the number of 
patients achieving an SVR by 311 000 and reduced the number of deaths from HCV to 470 
000 (a reduction of 121 000 deaths compared with risk-based screening). Compared with 
risk-based screening, birth-cohort screening increased QALYs by 532 000, medical costs by 
$19.0 billion, and productivity losses due to therapy by $6.7 billion. Productivity losses were 
not used to calculate ICER values.
The ICER of birth-cohort screening with standard treatment was $15 700 per QALY saved 
compared with risk-based treatment (Supplement 3, available at www.annals.org). The ICER 
of birth-cohort screening with DAA plus standard treatment was $35 700 per QALY saved 
compared with risk-based screening and $73 700 per QALY saved compared with birth-
cohort screening with standard treatment. When we considered only the incremental costs of 
screening, we estimated a cost of $2874 per new case of HCV identified.
The ICER of birth-cohort screening with standard treatment compared with risk-based 
screening was most sensitive to the inclusion of QALY losses from disease states before 
liver disease, the discount rate, and the probability of an SVR given genotype 1 disease. For 
this comparison, we estimated an ICER of $31 200 per QALY saved when we assumed no 
QALY losses from pre–liver disease states, $28 400 per QALY saved when we assumed a 
discount rate of 5%, and $20 100 per QALY saved when we assumed a 0.23 probability of 
an SVR for those with genotype 1 disease who initiated treatment (Figure 1).
When we assumed birth-cohort screening in both scenarios, the ICER of additional DAA 
treatment compared with standard treatment alone was $39 600 per QALY saved when we 
assumed an SVR probability of 0.70; the ICER was $337 000 per QALY saved when we 
assumed an SVR probability of 0.38 (data not shown). The ICER of additional DAA 
treatment compared with standard treatment alone was $19 600 when we assumed the costs 
were half our baseline value and was $114 200 when we assumed the costs were 50% 
higher.
We estimated that no screening was the most cost-effective up to a WTP of $16 000 per 
QALY gained, birth-cohort screening with standard treatment was the most cost-effective 
between a WTP of $16 000 and $75 000 per QALY, and birth-cohort screening with DAA 
and standard treatment was the most cost-effective at WTP values above that (Figure 2). 
When we dropped birth-cohort screening with standard treatment from our analysis and 
considered only the other 3 scenarios, no screening was the most cost-effective scenario up 
to a WTP of $16 000 per QALY, risk-based screening was most cost-effective between $16 
000 and $36 000 per QALY, and birth-cohort screening with DAA plus standard treatment 
was most cost-effective at WTP values of $36 000 per QALY saved and higher.
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Without new case identification strategies, the adverse consequences of chronic HCV 
infection are forecasted to result in an increasing public health burden over the next 2 
decades. Deaths from HCV are forecasted to double to more than 18 000 per year by 2020 
and to more than triple to 35 000 per year by 2030 (5). In this article, we investigated a new 
case identification strategy of screening those born from 1945 through 1965 (the birth cohort 
with the highest HCV prevalence) and estimated its cost-effectiveness by using conservative 
assumptions about the uptake and effectiveness of treatment. We found that compared with 
the current strategy of risk-based screening, birth-cohort screening followed by standard 
treatment reduced deaths by 82 300 at a cost of $15 700 per QALY gained (95% credible 
interval, $11 500 to $30 100). Incorporating new DAA treatments would prevent 
approximately 121 000 deaths compared with risk-based screening at a cost of $35 700 per 
QALY saved (95% credible interval, $28 200 to $47 200).
No universally accepted standard exists to determine what level of cost-effectiveness is 
appropriate to justify the implementation of a new strategy. However, by using the standards 
outlined by the National Committee on Prevention Priorities, birth-cohort screening with 
standard treatment alone when compared with risk-based screening ranks equivalently to 
colorectal cancer screening, hypertension screening, influenza vaccination of adults aged 50 
years or older, pneumococcal vaccination of adults aged 65 years or older, and vision 
screening of adults aged 65 years or older (63). Birth-cohort screening with DAA plus 
standard treatment (when compared with risk-based screening) ranks below those 
interventions but equivalently to cervical cancer or cholesterol screening (63).
If fully implemented, birth-cohort screening in primary care would identify 808 580 new 
cases (85.9% of all undiagnosed cases in the birth cohort, compared with 21.0% under risk-
based screening) at a screening cost of $2874 per new infection identified. This cost is 
similar to other estimated costs per new diagnosis of hepatitis B or C (30, 38). Birth-cohort 
screening is more costly than screening based on injection-drug use or elevated alanine 
aminotransferase levels, but those strategies probably miss many infected patients. The 
Centers for Disease Control and Prevention estimates that screening predicated on elevated 
alanine aminotransferase levels would identify less than half of the patients identified via 
birth-cohort screening (64). Furthermore, testing based on alanine aminotransferase 
elevations is already recommended in the Centers for Disease Control and Prevention’s 1998 
recommendations, but many persons with chronic HCV infection remain undiagnosed (12).
Our study has some limitations. First, to be conservative, we assumed that patients without 
insurance were not offered treatment, although many are currently offered treatment through 
compassionate use programs and clinical trial participation. Further, when the Affordable 
Care Act is fully implemented, insurance coverage will be extended to 95% of U.S. 
residents. Excluding uninsured persons from treatment limits our analysis by 
underestimating the aggregate benefits of the policy but has little effect on the cost-
effectiveness. Of note, if birth-cohort screening received an A- or a B-level recommendation 
from the U.S. Preventive Services Task Force, payment for screening would be mandated by 
the Affordable Care Act for all insurers (65).
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Second, our estimates of the costs and effectiveness of DAA plus standard treatment were 
necessarily speculative because clinical implementation data have yet to be reported. In our 
baseline analysis, in which we assumed a conservative probability of SVR (54%), our DAA 
plus standard treatment results were favorable when compared directly with risk-based 
screening and acceptable when compared with birth-cohort screening with standard care. 
Future research should replicate this analysis by using the real-world effectiveness and 
implementation costs of the DAAs telaprevir and boceprevir.
Third, fibrosis progression among undiagnosed persons is unknown. Our model capped the 
possible duration of disease before the start of the model at 20 years, an assumption that may 
underestimate disease progression in our population. The effect of this assumption is to 
make our screening intervention seem slightly less cost-effective than if we allowed for a 
longer possible duration at model initiation.
Fourth, as a simplification, we assumed that all screening (background and intervention) 
occurred in the first modeled year. This results in a slightly less favorable ICER than would 
a more realistic structure because it frontloads the costs of testing and treatment to the 
present time.
Fifth, our model does not incorporate elevated mortality risks from non-HCV causes among 
people with HCV but without past injection-drug use. Recent research indicates that excess 
mortality among these individuals for both hepatic and nonhepatic causes may be 
substantial, and this limitation probably led to a more favorable ICER (66).
Sixth, the NHANES data used for prevalence included only noninstitutionalized and 
nonhomeless populations. Institutionalized and homeless persons have a higher prevalence 
of HCV than NHANES respondents (67, 68), but they also have different competing risks 
for death and adherence to antiviral therapy. The effect of this limitation on cost-
effectiveness is unknown, so these analyses do not apply to institutional or homeless 
settings. Finally, we excluded the benefits of lifestyle counseling to slow disease 
progression, as well any benefits from averting secondary transmission; this approach led to 
a less favorable ICER.
We predicted that, compared with the status quo, birth-cohort screening would identify an 
additional 808 580 cases of HCV infection and prevent 82 000 HCV-related deaths, at a cost 
of $2874 per new case identified and $15 700 per QALY saved assuming standard treatment 
and $35 700 per QALY saved assuming DAA with standard therapy. Birth-cohort screening 
seems to be a reasonable strategy to identify asymptomatic cases of HCV.
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Most people in the United States infected with hepatitis C virus (HCV) were born from 
1945 through 1965 and are undiagnosed. Because complications of hepatitis C increase 
with time, its burden is now rapidly increasing.
Contribution
In simulated models, an approach of 1-time screening for hepatitis C in this birth cohort 
followed by treatment was cost-effective.
Caution
Data on the real-world effectiveness of newer drugs for hepatitis C are extremely limited.
Implication
A change from solely risk-based screening for hepatitis C to 1-time screening of all 
persons born from 1945 through 1965 should be considered.
—The Editors
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Figure 1. Univariate sensitivity of the incremental cost-effectiveness ratio of birth-cohort 
screening with standard treatment compared with risk-based screening assuming pegylated 
interferon with ribavirin treatment
QALY = quality-adjusted life-year; SVR = sustained viral response.
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Figure 2. Cost-effectiveness acceptability curve: probability that each screening scenario is the 
most cost-effective by willingness to pay per incremental QALY gained
Birth cohort, standard treatment = 1-time screening of all individuals born from 1945 
through 1965 with pegylated interferon with ribavirin (i.e., standard) treatment for those 
who enter treatment; birth cohort, direct-acting antivirals = 1-time screening of all 
individuals; no screening = no screening or treatment; risk-based = status quo equivalent of 
screening based on identified risk factors followed by pegylated interferon with ribavirin 
treatment for those who enter treatment. QALY = quality-adjusted life-year.
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